FY2024 EPS Estimates for Genmab A/S Increased by Analyst

Genmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair lifted their FY2024 earnings estimates for Genmab A/S in a report issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $1.24 per share for the year, up from their previous estimate of $1.22. The consensus estimate for Genmab A/S's current full-year earnings is $1.29 per share. William Blair also issued estimates for Genmab A/S's Q4 2024 earnings at $0.34 EPS, FY2025 earnings at $1.60 EPS, FY2026 earnings at $2.52 EPS and FY2027 earnings at $3.56 EPS.

A number of other research firms have also weighed in on GMAB. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, September 9th. Morgan Stanley reaffirmed an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Trading Down 0.1 %

Shares of GMAB traded down $0.03 during trading hours on Friday, reaching $23.08. The stock had a trading volume of 1,560,527 shares, compared to its average volume of 675,316. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 0.68 and a beta of 0.99. The firm has a 50-day simple moving average of $24.39 and a 200 day simple moving average of $26.41. Genmab A/S has a 12 month low of $21.90 and a 12 month high of $32.89.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Genmab A/S in the 1st quarter worth about $43,000. Janney Montgomery Scott LLC increased its stake in shares of Genmab A/S by 43.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company's stock worth $520,000 after purchasing an additional 5,238 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Genmab A/S by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company's stock valued at $830,000 after purchasing an additional 633 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Genmab A/S by 360.5% during the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company's stock valued at $882,000 after buying an additional 23,094 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after acquiring an additional 544 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.